About Prelude Therapeutics
Prelude Therapeutics is a publicly listed company based in Philadelphia (United States) founded in 2016 by Kris Vaddi. Chromatin-targeting drugs are developed for cancer and rare diseases. It operates on a HealthTech model. Prelude Therapeutics has raised $145 million across 4 funding rounds from investors including Fidelity Investments and Orbimed. The company has 131 employees. Its chief executive, as recorded, is Kris Vaddi. Prelude Therapeutics offers products and services including SMARCA2 Degraders, KAT6A Degraders, Precision ADCs, and CDK Inhibitors. Its focus areas include Biotechnology and Oncology. Its competitors include Revolution Medicines, Blueprint Medicines and Syndax; 3 of its 3 listed competitors have raised funding.
Company details
Prelude Therapeutics is engaged in the discovery and development of innovative cancer medicines. The company specializes in precision oncology, targeting high unmet needs with novel drug candidates. Programs include first-in-class SMARCA2 and KAT6A degraders, alongside precision antibody-drug conjugates (ADCs). Their expertise in targeted protein degradation is leveraged to advance next-generation therapies. Collaborations with partners like AbCellera enhance their ADC development. The focus remains on extending precision medicine benefits to cancer patients across various tumor types and resistance mechanisms.
- Headquarters Philadelphia, United States
- Employees 131
- Founders Kris Vaddi
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website preludetx.com
- Social LinkedIn X
- Legal Name Prelude Therapeutics Incorporated
- Annual Revenue$12.14 M (USD)73.43as on Dec 31, 2025
- Net Profit-$99.5 M (USD)21.76as on Dec 31, 2025
- EBITDA-$102.86 M (USD)25.44as on Dec 31, 2025
- Total Equity Funding$145M (USD)
in 4 rounds
- Latest Funding Round$50M (USD), Series C
Aug 2020
- InvestorsFidelity Investments
& 1 more
- Employee Count131
Products & Services of Prelude Therapeutics
Prelude Therapeutics offers a comprehensive portfolio of products and services, including SMARCA2 Degraders, KAT6A Degraders, Precision ADCs, and CDK Inhibitors.
SMARCA2 degraders are developed for cancer treatment efficacy.
KAT6A degraders are designed for breast cancer treatment.
Precision ADCs are created for targeted cancer therapy.
CDK inhibitors are formulated for various cancer treatments.
Funding Insights of Prelude Therapeutics
Prelude Therapeutics has successfully raised a total of $145M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $50 million completed in August 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $145M
- Total Rounds 4
- Last Round Series C — $50M
- First Round $5M
(Jul 2016)
- Investors Count 2
All 4 funding rounds of Prelude Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2020 | $50M | Series C | – | Fidelity Investments | |
| Jun 2019 | $60M | Series B | – | Orbimed | – |
| Aug 2018 | $30M | Series B | – | – | – |
| Jul 2016 | $5M | Series A | – | – | – |
2 investors in total: 2 institutional.
Investors in Prelude Therapeutics
Prelude Therapeutics has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Provider of brokerage accounts, retirement planning, wealth management, and trading platforms | 1946 | fidelity.com | Boston, United States |
Investor details for Prelude Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Prelude Therapeutics
50 people are tracked at Prelude Therapeutics (29 in leadership, 5 in board & advisors, 16 in team); the tracked headcount is 131.
| Name | Role | Group |
|---|---|---|
Kris Vaddi | Founder & CEO | Leadership |
Jane Huang | President & Chief Medical Officer | Leadership |
Aimee Crombie | SVP & Head of Strategic Planning & Operations | Leadership |
Michele Porreca | Chief People Officer | Leadership |
Andrew Combs | EVP & Head of Chemistry | Leadership |
Siminder Kaur Atwal | Executive Director, Clinical Development | Leadership |
Jian Ren | Director, Drug Product Analytics | Leadership |
Jack Carter | Director, Biology | Leadership |
Xiaowei Wu | Director, Chemistry | Leadership |
Bryant Lim | Cfo, Chief Legal Officer And Secretary | Leadership |
Askold Sandursky | Vice President, Head Of Information Technologies | Leadership |
Jeffrey Edonick | Associate Director Of Information Technology | Leadership |
Jane H. | President And Chief Medical Officer | Leadership |
Tim Mueller | Vice President Ehs, Lab Operations, & Facilities | Leadership |
Murty Mangena | Executive Director Technical Operations | Leadership |
Erin Hugger Difilippo | Vice President Of Business Development | Leadership |
Sandy Geeganage | Vice President - Drug Discovery | Leadership |
Kenneth Ray | Senior Director, Analytical Chemistry | Leadership |
Ganfeng Cao 曹敢峰 | Vice President And Head Of Process Chemistry, CMC | Leadership |
Min Wang | Director | Leadership |
30 more people are available in the full profile.
Complete people profiles for Prelude Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Prelude Therapeutics
Prelude Therapeutics is a publicly listed company on the NASDAQ with ticker symbol PRLD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date25 Sep 2020
- Listed onNASDAQ: PRLD
- Listed entityPrelude Therapeutics Incorporated
- Exchange sectorHealth technology
- ISINUS74065P1012
- Share price$3.56 (-4.81% on the day) · 2026-10-13
- Market capitalisation$284.1M
- EPS (diluted, trailing year)$-0.79
- Volume (last session)676,363
Financials of Prelude Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $12.1M | -$99.5M | -$102.9M |
| 2024 | $7.0M | -$127.2M | -$137.9M |
| 2023 | -$121.8M | -$131.1M | |
| 2022 | -$115.4M | -$120.5M | |
| 2021 | -$111.7M | -$111.5M |
Detailed financial statements for Prelude Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Prelude Therapeutics
4 dated milestones of Prelude Therapeutics across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Prelude Therapeutics is founded.
- Funding First funding round of $5.0M.
- Funding Latest funding round, Series C, of $50.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Prelude Therapeutics
Prelude Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Revolution Medicines, Blueprint Medicines and Syndax.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.29M | 107 | Targeted therapies for cancer treatment are developed. |
Detailed competitors of Prelude Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Prelude Therapeutics
The website of Prelude Therapeutics (preludetx.com) receives about 6.9K visits a month and ranks #3,105,631 among all websites worldwide, #4,103 in Biotechnology and Pharmaceuticals.
- Monthly visits6.9K
▲ 16.9% vs previous month
- Unique visitors2.2K
per month
- Global rank#3,105,631
among all websites
- Category rank#4,103
Health · Biotechnology and Pharmaceuticals
- Bounce rate36%
- Pages per visit2.1
- Average visit47 sec
- DevicesDesktop 52% · Mobile 48%
Websites whose visitors overlap most with Prelude Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
dermlasersurgery.com | dermlasersurgery.com | 100% | #3,187,901 | – | |
ashpublications.org | ashpublications.org | 67% | #71,572 | – | |
annalsofoncology.org | annalsofoncology.org | 67% | #169,085 | – |
Top companies in Oncology
3 companies that operate in the same segment as Prelude Therapeutics (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Prelude Therapeutics
Complete news archive for Prelude Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Prelude Therapeutics
Prelude Therapeutics was founded in 2016.
Prelude Therapeutics is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Kris Vaddi is the CEO of Prelude Therapeutics, as recorded in our data. They have also founded this company.
Prelude Therapeutics is a funded company, having raised a total of $145M across 4 funding rounds to date. The company's 1st funding round was a Series A of $5M, raised on Jul 2016.
Prelude Therapeutics has 131 employees.
Annual revenue of Prelude Therapeutics is $12.14M as on Dec 31, 2025.
Prelude Therapeutics is engaged in the discovery and development of innovative cancer medicines. The company specializes in precision oncology, targeting high unmet needs with novel drug candidates. Programs include first-in-class SMARCA2 and KAT6A degraders, alongside precision antibody-drug conjugates (ADCs). Their expertise in targeted protein degradation is leveraged to advance next-generation therapies. Collaborations with partners like AbCellera enhance their ADC development. The focus remains on extending precision medicine benefits to cancer patients across various tumor types and resistance mechanisms.
Prelude Therapeutics's top competitors include Syndax, Revolution Medicines and Blueprint Medicines.
Prelude Therapeutics offers SMARCA2 Degraders, KAT6A Degraders, Precision ADCs, and CDK Inhibitors.
Yes, Prelude Therapeutics is publicly traded on NASDAQ under the ticker symbol PRLD.
Prelude Therapeutics has 2 investors. Key investors include Fidelity Investments, and Orbimed.
Prelude Therapeutics operates through Prelude Therapeutics.